Pular para o conteúdo principal
Ranking Invest

HCM - HUTCHMED (China) Limited

Segmento: HealthcareHUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Análise Ranking Invest

Valuation estimado
-9,14%
$ 304.02 Mi
Valor de Mercado
$ 2.25 Bi
Sobrepreço (AV)+641.4%
IVR
0.13A companhia vale 0,13 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.20O valuation alternativo equivale a -20% do valor de mercado da companhia.
MLL
-0.20O lucro líquido dos controladores em 16 trimestres equivale a -20% do valor de mercado.
Último Balanço Atualizado: 4T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 748.00 Mi

Dívida Líquida

-$ 64.14 Mi

L4T

$ 37.73 Mi

MM4T

6.06%

Indicadores Básicos

ROE

5.04%

Índices de Previsibilidade

Receita Líquida

E0.26

Lucro

F4.74

Margem

D1.07

Índices de Tendência

Receita Líquida

C5.60

Lucro

B6.16

Margem

A8.35

Índices de Endividamento

DIV/PAT

-0.09

DIV/L4T

-1.70

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.